Navigation Links
StemGenex to Launch Adult Stem Cell-Based Therapy to Relieve COPD Symptoms
Date:9/20/2012

LA JOLLA, Calif., Sept. 20, 2012 /PRNewswire/ -- New developments in regenerative medicine are bringing about exciting, novel approaches to create therapies for hard to treat diseases. Chronic obstructive pulmonary disease (COPD) is a hard to treat disorder that progressively blocks airflow in the lungs making it increasingly difficult for an individual to breathe, and is one of the leading illnesses in the US. Yet, current treatments for COPD can only try to limit the extent of damage to the lungs, and to bring some relief from symptoms. Novel treatments for COPD are urgently needed, and new applications with the use of adult stem cells may have much benefit. This is because adult stem cells have an ability to differentiate into many different types of cells, such as those required for healthy, functioning lung tissue. Also, adult stem cells can be isolated with ease from an individual's own fat tissue, and so adult stem cell therapy is not subject to the ethical or religious issues that trouble some other methods.

(Photo: http://photos.prnewswire.com/prnh/20120920/LA78252)

StemGenex, a US based company, is finding new avenues and methods for using adipose derived adult stem cells to help in diseases with limited treatment options. StemGenex has been working with scientists and physicians over the last 5 years to specifically advance adult stem cell treatment protocols, and the hope is that COPD adult stem cell therapy can help in alleviating COPD symptoms. Results from researchers working with adult stem cells have shown anti-inflammatory and immune modulatory effects, suggesting possible roles in treating COPD. Interestingly, recent studies in mice indicate the presence of stem cells in the lungs can regenerate damaged lung tissue which occurs through infection. Encouragingly, adult stem cell treatment studies in mice appear to have positive effects across a range of respiratory diseases, which includes COPD.

Taking these research findings into account and building on their own developments, StemGenex is about to submit a plan of using adult stem cell therapy for COPD treatment to an Institutional Review Board for review. This study could scientifically define any potential benefits of such clinical treatments. Rita Alexander, the President of StemGenex, says, "Chuck Liptak, a long-term COPD sufferer, eliminated his requirement for oxygen following a stem cell treatment.  It's imperative that these results be scientifically quantified."  

To find out more about stem cell treatments contact StemGenex. An experienced stem cell physician reviews the patient evaluation and a patient can have any questions or requests for more detailed information addressed by a patient advocate. StemGenex™ is based in La Jolla, California with treatment locations on the east and west coast.

Contact:
La Jolla Cove Research Center
505 Coast Boulevard South
La Jolla, CA 92037
858-459-STEM (7836)
Contact@StemGenex.com
http://www.StemGenex.com


'/>"/>
SOURCE StemGenex
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
2. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
3. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
4. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
5. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
6. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
7. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
8. Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
9. Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio
10. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
11. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016  The Multiple Myeloma Research Foundation (MMRF) today ... Study SM —the largest and most comprehensive study driving ... myeloma—will be presented at the 58 th American ... San Diego from December 3-6. ... as well as identify pathways and targets for new ...
(Date:12/2/2016)... ... 2016 , ... ACEA Biosciences, Inc. announced today that it will be presenting ... the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 01, 2016 , ... ... event is expanding to three days and will take place on February 1-3, 2017 ... (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which ...
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
Breaking Biology Technology:
(Date:11/17/2016)... INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has just ... servers in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):